Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 400,000 ordinary shares of 25 pence each.
- Purchase Price: 1,480.85 pence per share.
- Treasury Holdings Post-Transaction: 180,151,678 shares.
- Shares in Issue (Excluding Treasury): 5,804,307,018 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 400,000 shares on July 19, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 400,000 share repurchase based on the disclosed price of 1,480.85 pence per share.
- Confirm the updated total share capital structure, noting the increase in Treasury shares to 180,151,678.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and capital allocation strategy.